Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 4.75%46.94B | 4.79%11.42B | 4.71%12.42B | 5.37%11.77B | 4.10%11.33B | 4.82%44.81B | 1.16%10.9B | 4.34%11.86B | 7.93%11.17B | 6.08%10.88B |
Cost of revenue | 6.33%43.14B | 5.80%10.44B | 6.91%11.44B | 6.90%10.9B | 5.66%10.37B | 5.24%40.57B | 1.03%9.87B | 4.33%10.7B | 9.04%10.2B | 6.86%9.81B |
Gross profit | -10.42%3.8B | -4.94%982M | -15.25%989M | -10.71%867M | -10.20%960M | 1.00%4.24B | 2.48%1.03B | 4.20%1.17B | -2.41%971M | -0.56%1.07B |
Operating expense | 11.39%1.18B | 9.30%282M | 7.41%290M | 17.03%323M | 11.63%288M | 8.26%1.06B | 9.79%258M | 5.88%270M | 9.96%276M | 7.50%258M |
Operating profit | -17.72%2.62B | -9.68%700M | -22.07%699M | -21.73%544M | -17.14%672M | -1.21%3.18B | 0.26%775M | 3.70%897M | -6.59%695M | -2.87%811M |
Net non-operating interest income (expenses) | -123.53%-76M | -122.22%-20M | -90.00%-19M | -150.00%-20M | -142.86%-17M | -9.68%-34M | -28.57%-9M | -25.00%-10M | 0.00%-8M | 12.50%-7M |
Non-operating interest income | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Non-operating interest expense | 123.53%76M | 122.22%20M | 90.00%19M | 150.00%20M | 142.86%17M | 9.68%34M | 28.57%9M | 25.00%10M | 0.00%8M | -12.50%7M |
Net investment income | -69.23%8M | 1M | -80.00%2M | -77.78%2M | -57.14%3M | -21.21%26M | 0 | 100.00%10M | -50.00%9M | -12.50%7M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 0 | 0 | 0 | 0 | 249M | 0 | 249M | 0 | 0 |
Income from associates and other participating interests | ||||||||||
Special income (charges) | 108.89%24M | -16.67%-7M | -16.67%10M | 109.27%24M | 82.35%-3M | -970.97%-270M | -6M | -50.00%12M | -3,337.50%-259M | -1,600.00%-17M |
Less:Other special charges | -108.89%-24M | 16.67%7M | 16.67%-10M | -109.27%-24M | -82.35%3M | 943.75%270M | --6M | 52.00%-12M | 3,337.50%259M | 1,600.00%17M |
Other non-operating income (expenses) | 18.57%83M | 34.78%31M | 95.65%45M | -57.14%3M | -76.47%4M | 40.00%70M | -8.00%23M | 43.75%23M | 800.00%7M | 70.00%17M |
Income before tax | -17.51%2.66B | -9.94%707M | -37.68%736M | 25.45%557M | -18.99%657M | -2.39%3.22B | -0.76%785M | 30.64%1.18B | -41.73%444M | -3.80%811M |
Income tax | -34.72%611M | -88.89%22M | -37.08%224M | 24.06%165M | -19.68%200M | -2.19%936M | 12.50%198M | 28.06%356M | -42.67%133M | -8.12%249M |
Net income | -10.46%2.05B | 16.52%684M | -37.74%513M | 25.32%391M | -18.54%457M | -2.48%2.28B | -4.40%587M | 31.42%824M | -41.02%312M | -1.92%561M |
Net income continuous operations | -10.46%2.05B | 16.70%685M | -37.94%512M | 26.05%392M | -18.68%457M | -2.48%2.29B | -4.55%587M | 31.79%825M | -41.32%311M | -1.75%562M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | -10.46%2.05B | 16.52%684M | -37.74%513M | 25.32%391M | -18.54%457M | -2.48%2.28B | -4.40%587M | 31.42%824M | -41.02%312M | -1.92%561M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -10.46%2.05B | 16.52%684M | -37.74%513M | 25.32%391M | -18.54%457M | -2.48%2.28B | -4.40%587M | 31.42%824M | -41.02%312M | -1.92%561M |
Gross dividend payment | ||||||||||
Basic earnings per share | -10.48%274 | 16.48%91.6 | -37.73%68.74 | 25.27%52.4 | -18.56%61.26 | -2.51%306.08 | -4.51%78.64 | 31.57%110.39 | -41.08%41.83 | -1.93%75.22 |
Diluted earnings per share | -10.48%274 | 16.47%91.5926 | -37.74%68.7246 | 25.27%52.3807 | -18.56%61.26 | -2.51%306.08 | -4.44%78.638 | 31.57%110.388 | -41.03%41.8142 | -1.93%75.22 |
Dividend per share | 0.00%94 | 0.00%47 | 0 | 0.00%47 | 0 | 17.50%94 | 17.50%47 | 0 | 17.50%47 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |